EMEA-002169-PIP01-17-M03 - paediatric investigation plan
Setrusumab
PIPHuman
Key facts
- Active Substance
- Setrusumab
- Therapeutic area
- Other
- Decision number
- P/0225/2024
- PIP number
- EMEA-002169-PIP01-17-M03
- Pharmaceutical form(s)
- Powder for solution for injection
- Condition(s) / indication(s)
- Treatment of osteogenesis imperfecta
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Mereo Biopharma Ireland Limited
Email: bharti.navsariwala@mereobiopharma.com
Tel.: +44 3330237342- Decision type
- PM: decision on the application for modification of an agreed PIP
- Decision date